RNAO+Aptamers the same as mRNA?
Nope! RNAO+Aptamers may be produced the same way and on the same equipment as mRNA, but unlike all other RNA technologies, it does not encode any genetic information. It is used for structural purposes only.
.jpg)
35x
30x
25x
20x
15x
10x
5x
0
Buffer
Apt 1
Apt 2
Linked
Apt 1 + 2
Origami
Platform
RNAO + Apatmers
Efficacy
Helixomer's Solution: Unleashing the Promise of Aptamers
Although polyethylene glycol (PEG) extends the therapeutic availability time of aptamers, it does not improve binding efficacy and worse, it induces an immune response.
Helixomer's RNA Origami (RNAO) platform technology enhances aptamer performance by structurally optimizing their arrangement and placing multiple aptamers on each molecule, significantly boosting efficacy while maintaining non-immunogenic properties. This platform also supports modular drug design, utilizing established mRNA production facilities for scalable synthesis, which allows for rapid adaptation of aptamers to various therapeutic needs.
Unleashing Aptamer Therapeutics with
RNA Origami (RNAO)
Why Have Aptamers on RNAO?
What are aptamers?
Aptamers are small, nonimmunogenic, antibody-like, lab-made molecules that bind precisely to specific targets, such as peptides, proteins, or even whole cells.
Numerous aptamers have entered clinical trials since their discovery (1990), yet only two have achieved FDA approval due to low efficacy and rapid elimination of therapeutic availability because of small size.
Aptamers vs. Antibodies
